Although it is being investigated in several types of carcinomas, its effects in cervical cancer have not been established.59 In a recent study, Alpelisib suppressed PIK3CA-mutant cervical carcinoma cell proliferation and migration in vitro (ME-180) and in vivo.60 Furthermore, mutations in PIK3CA are also associated with higher rates of mutations in other genes of important cancer-associated pathways, such as the tyrosine kinase receptors/K-Ras/BRAF/MAPK and the Wnt/β catenin pathways.61 The gene discussed is KRAS; the disease is cervical carcinoma.